These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 9815772

  • 1. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B.
    Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
    [Abstract] [Full Text] [Related]

  • 2. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P, Ng CP, Belldegrun A, Bonavida B.
    Cell Immunol; 1997 Aug 25; 180(1):70-83. PubMed ID: 9316641
    [Abstract] [Full Text] [Related]

  • 3. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug 25; 160(2):561-70. PubMed ID: 9679929
    [Abstract] [Full Text] [Related]

  • 4. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
    Uslu R, Jewett A, Bonavida B.
    Gynecol Oncol; 1996 Aug 25; 62(2):282-91. PubMed ID: 8751562
    [Abstract] [Full Text] [Related]

  • 5. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
    Borsellino N, Belldegrun A, Bonavida B.
    Cancer Res; 1995 Oct 15; 55(20):4633-9. PubMed ID: 7553641
    [Abstract] [Full Text] [Related]

  • 6. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P, Caliliw R, Belldegrun A, Bonavida B.
    Int J Oncol; 2003 Feb 15; 22(2):431-7. PubMed ID: 12527945
    [Abstract] [Full Text] [Related]

  • 7. Fas-mediated apoptosis in human prostatic carcinoma cell lines.
    Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB.
    Cancer Res; 1997 May 01; 57(9):1758-68. PubMed ID: 9135020
    [Abstract] [Full Text] [Related]

  • 8. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
    Liu QY, Rubin MA, Omene C, Lederman S, Stein CA.
    Clin Cancer Res; 1998 Jul 01; 4(7):1803-11. PubMed ID: 9676859
    [Abstract] [Full Text] [Related]

  • 9. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.
    J Immunol; 2001 Mar 01; 166(5):3564-73. PubMed ID: 11207317
    [Abstract] [Full Text] [Related]

  • 10. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
    Frost PJ, Belldegrun A, Bonavida B.
    Prostate; 1999 Sep 15; 41(1):20-30. PubMed ID: 10440872
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O.
    Cancer Res; 2000 Jun 01; 60(11):2912-8. PubMed ID: 10850437
    [Abstract] [Full Text] [Related]

  • 12. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
    Sun SY, Yue P, Lotan R.
    Oncogene; 2000 Sep 14; 19(39):4513-22. PubMed ID: 11002424
    [Abstract] [Full Text] [Related]

  • 13. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
    Morimoto H, Yonehara S, Bonavida B.
    Cancer Res; 1993 Jun 01; 53(11):2591-6. PubMed ID: 7684321
    [Abstract] [Full Text] [Related]

  • 14. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
    Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, Yagita H, Okumura K, Imawari M.
    J Immunol; 1997 Jun 01; 158(11):5283-91. PubMed ID: 9164947
    [Abstract] [Full Text] [Related]

  • 15. Fas (CD95, APO-1) antigen expression and function in murine mast cells.
    Hartmann K, Wagelie-Steffen AL, von Stebut E, Metcalfe DD.
    J Immunol; 1997 Oct 15; 159(8):4006-14. PubMed ID: 9378990
    [Abstract] [Full Text] [Related]

  • 16. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
    Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R, Wiltrout RH.
    J Immunol; 1998 Oct 15; 161(8):3957-65. PubMed ID: 9780164
    [Abstract] [Full Text] [Related]

  • 17. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G.
    J Immunol; 1998 Aug 01; 161(3):1220-30. PubMed ID: 9686582
    [Abstract] [Full Text] [Related]

  • 18. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S, Vega M, Garban H, Bonavida B.
    Clin Immunol; 2006 Sep 01; 120(3):297-309. PubMed ID: 16784892
    [Abstract] [Full Text] [Related]

  • 19. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.
    Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S.
    J Immunol; 1996 Oct 01; 157(7):2909-15. PubMed ID: 8816396
    [Abstract] [Full Text] [Related]

  • 20. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
    Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, Peter ME, Wyche JH, Pantazis P.
    Cancer Res; 2001 Oct 01; 61(19):7148-54. PubMed ID: 11585748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.